Premium
Lansoprazole does not affect the bioavailability of oral contraceptives.
Author(s) -
Fuchs W,
Sennewald R,
Klotz U
Publication year - 1994
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1994.tb04370.x
Subject(s) - lansoprazole , bioavailability , levonorgestrel , placebo , cmax , ethinylestradiol , medicine , pharmacokinetics , confidence interval , pharmacology , population , family planning , research methodology , alternative medicine , environmental health , pathology , omeprazole
The effects of the proton pump inhibitor lansoprazole on the bioavailability of a low‐dose oral contraceptive (OC), containing 0.03 mg ethinyloestradiol (EE) and 0.15 mg levonorgestrel (LNG), were investigated. Twenty‐four healthy females (aged 19‐35 years; weight 60.6 +/‐ 7.1 kg) participated in a multiple‐dose, placebo‐controlled, randomized two‐way cross‐over study. All subjects received the OC over 2 full menstrual cycles from day 1 to day 21 separated by a drug‐free interval of 7 days. Lansoprazole (60 mg day‐1) or placebo was coadministered for 3 weeks each. Plasma concentrations of EE and LNG were determined by GC‐MS. The 90% confidence intervals for ratios of Cmax and AUC after log transformation of both EE and LNG ranged between 91 and 111%, indicating that lansoprazole did not affect the bioavailability of EE and LNG.